Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test (Business Wire)

Guardant Health announced updated clinical results for its Shield™ blood test, showing 84% sensitivity and 90% specificity for detecting colorectal cancer (CRC) with its new V2 algorithm, including 62% sensitivity in stage I disease. The findings, validated in an expanded ECLIPSE study cohort, met all primary endpoints and highlighted robust early-stage detection (100% sensitivity in stage II and IV). Shield remains the first and only FDA-approved blood test for primary CRC screening in average-risk adults and was recently added to NCCN guidelines. The platform is also being expanded into multi-cancer detection.